These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9740686)

  • 1. Multiple drug resistance parameter expression in ovarian cancer.
    Joncourt F; Buser K; Altermatt H; Bacchi M; Oberli A; Cerny T
    Gynecol Oncol; 1998 Aug; 70(2):176-82. PubMed ID: 9740686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
    Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
    Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
    Redmond SM; Joncourt F; Buser K; Ziemiecki A; Altermatt HJ; Fey M; Margison G; Cerny T
    Cancer Res; 1991 Apr; 51(8):2092-7. PubMed ID: 1672623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
    Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
    Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors.
    Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L
    Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics.
    Buser K; Joncourt F; Altermatt HJ; Bacchi M; Oberli A; Cerny T
    Ann Oncol; 1997 Apr; 8(4):335-41. PubMed ID: 9209662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer.
    Oberli-Schrämmli AE; Joncourt F; Stadler M; Altermatt HJ; Buser K; Ris HB; Schmid U; Cerny T
    Int J Cancer; 1994 Dec; 59(5):629-36. PubMed ID: 7960235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma].
    Yu DQ; Yi YF
    Ai Zheng; 2003 May; 22(5):496-9. PubMed ID: 12753710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemia.
    Joncourt F; Oberli A; Redmond SM; Fey MF; Tobler A; Margison GP; Gratwohl A; Buser K; Cerny T
    Br J Haematol; 1993 Sep; 85(1):103-11. PubMed ID: 7902732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
    Akçay T; Dinçer Y; Alademir Z; Aydinli K; Arvas M; Demirkiran F; Kösebay D
    Eur J Obstet Gynecol Reprod Biol; 2005 Mar; 119(1):108-13. PubMed ID: 15734094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of glutathione S-transferase and its Pi isoenzyme in tumor tissues and sera of patients with ovarian cancer.
    Ghalia AA; Rabboh NA; el Shalakani A; Seada L; Khalifa A
    Anticancer Res; 2000; 20(2B):1229-35. PubMed ID: 10810426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
    Pawlik CA; Israel M; Sweatman TW; Lothstein L
    Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
    Luan YZ; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.
    Beeghly A; Katsaros D; Chen H; Fracchioli S; Zhang Y; Massobrio M; Risch H; Jones B; Yu H
    Gynecol Oncol; 2006 Feb; 100(2):330-7. PubMed ID: 16199080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.